Molecular imaging in the management of cervical cancer

Journal of the Formosan Medical Association

Volumn 111, Issue 8, 2012, Pages 412-420

  Lai, Chyong Huey ^a   Yen, Tzu Chen ^a   Ng, Koon Kwan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cervical cancer; Molecular imaging; MRI; PET; PET CT

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB;

CANCER RECURRENCE; CANCER STAGING; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DRUG TARGETING; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; UTERINE CERVIX CANCER;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84865588571     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.02.024     Document Type: Review

References (66)

1. Ferlay J., Shin H., Bray F., Forman D., Mathers C., Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:IARC CancerBase No 10 2010, International Agency for Research on Cancer, Lyon, France, [accessed 14.10.11]. http://globocan.iarc.fr.
2. Pecorelli S., Zigliani L., Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Obstet Gynecol 2009, 105:107-108.
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Cervical Cancers Version 1.2012. [accessed 26.10.11]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Lai C.H., Chang C.J., Huang H.J., Hsueh S., Chao A., Lin C.T., et al. Role of HPV genotype in prognosis of cervical cancer undergoing primary surgery. J Clin Oncol 2007, 25:3628-3634.
5. Wang C.C., Lai C.H., Huang H.J., Chao A., Chang C.J., Chang T.C., et al. Clinical Impact of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1111-1120.
6. Mitchell D.G., Snyder B., Coakley F., Reinhold C., Thomas G., Amendola M., et al. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 intergroup study. J Clin Oncol 2006, 24:5687-5694.
7. Hricak H., Gatsonis C., Coakley F.V., Snyder B., Reinhold C., Schwartz L.H., et al. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation-ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology 2007, 245:491-498.
8. Juweid M.E., Cheson B.D. Positron-emission tomography and assessment of cancer therapy. New Engl J Med 2006, 354:469-507.
9. Yu J.Q., Cristofanilli M. Circulating tumor cells and PET. J Nucl Med 2011, 52:1501-1504.
10. Torizuka T., Kanno T., Futatsubashi M., Okada H., Yoshikawa E., Nakamura F., et al. Imaging of gynecologic tumors: comparison of 11C-choline PET with 18F-FDG PET. J Nucl Med 2003, 44:1051-1056.
11. 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
12. 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008, 49:1177-1182.
13. Breeman W.A.P., Verbruggen A.M. The 68 Ge/68Ga generator has high potential, but when can we use 68 Ga-labelled tracers in clinical routine?. Eur J Nucl Med Mol Imaging 2007, 34:978-981.
14. Rice S.L., Roney C.A., Daumar P., Lewis J.S. The next generation of PET radiopharmaceuticals in oncology. Semin Nucl Med 2011, 41:265-282.
15. Kenny L.M., Coombes R.C., Oulie I., Contractor K.B., Miller M., Spinks T.J., et al. Phase I trial of the positron emitting ArgGlyAsp (RGD) peptide radioligand 18 F-AH111585 in breast cancer patients. J Nucl Med 2008, 49:879-886.
16. Boerman O.C., Oyen W.J.G. Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med 2011, 52:1171-1172.
17. Lin Y.C., Lin G., Chen Y.R., Yen T.C., Wang C.C., Ng K.K. Role of magnetic resonance imaging and apparent diffusion coefficient at 3T in distinguishing between adenocarcinoma of the uterine cervix and endometrium. Chang Gung Med J 2011, 34:93-100.
18. Charles-Edwards E., Morgan V., Attygalle A.D., Giles S.L., Ind T.E., Davis M., et al. Endovaginal magnetic resonance imaging of stage 1A/1B cervical cancer with A T2- and diffusion-weighted magnetic resonance technique: effect of lesion size and previous cone biopsy on tumor detectability. Gynecol Oncol 2011, 120:368-373.
19. Gallagher F.A., Bohndiek S.E., Kettunen M.I., Lewis D.Y., Soloviev D., Brindle K.M., et al. Hyperpolarized 13C MRI and PET: in vivo tumor biochemistry. J Nucl Med 2011, 52:1333-1336.
20. Narayanan P., Lyngkaran, Sohaib S.A., Lewis D.Y., Soloviev D., Brindle K.M. Pearls and pitfalls of MR lymphography in gynecologic malignancy. Radiographics 2009, 29:1057-1071.
21. Showalter T.N., Miller T.R., Huettner P., Rader J., Grigsby P.W. 18F-fluorodeoxyglucose positron emission tomography and pathologic tumor size in early-stage invasive cervical cancer. Int J Gynecol Cancer 2009, 19:1412-1414.
22. Yilmaza M., Adlib M., Celen Z., Zincirkeser S., Dirier A. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential. Nucl Med Commun 2010, 31:526-531.
23. Yen T.C., See L.C., Lai C.H., Yen T.C., See L.C., Lai C.H., et al. Standardized uptake value in paraaortic lymph node is a significant prognostic factor in primary advanced squamous cervical cancer. Eur J Nucl Med 2008, 35:493-501.
24. Kidd E.A., Siegel B.A., Dehdashti F., Rader J.S., Mutch D.G., Powell M.A., et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010, 28:2108-2113.
25. Grigsby P.W., Siegel B.A., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001, 19:3745-3749.
26. Yamashita H., Nakagawa K., Tago M., Shiraishi K., Nakamura N., Ohtomo K. Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix. Br J Radiol 2005, 78:821-826.
27. Kim S.K., Choi H.J., Park S.Y., Lee H.Y., Seo S.S., Yoo C.W., et al. Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer 2009, 45:2103-2109.
28. Tsai C.S., Lai C.H., Chang T.C., Yen T.C., Ng K.K., Hsueh S., et al. A prospective randomized trial to study the impact of pre-treatment FDG-PET for cervical cancer with positive pelvic nodes but negative para-aortic node shown on MRI. Int J Radiat Oncol Biol Phys 2010, 76:477-484.
29. Ramirez P.T., Jhingran A., Macapinlac H.A., Euscher E.D., Munsell M.F., Coleman R.L., et al. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer. Cancer 2011, 117:1928-1934.
30. Kang S., Park J.Y., Lim M.C., Song Y.J., Park S.H., Kim S.K., et al. Pelvic lymph node status assessed by 18F-fluorodeoxyglucose positron emission tomography predicts low-risk group for distant recurrence in locally advanced cervical cancer: a prospective study. Int J Radiat Oncol Biol Phys 2011, 79:788-793.
31. Chao A., Ho K.C., Wang C.C., Lin G., Cheng H.H., Yen T.C., et al. Positron emission tomography in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol 2008, 110:171-178.
32. Qiu J.T., Ho K.C., Lai C.H., Yen T.C., Lin G., Huang Y.T., et al. Supraclavicular lymph node metastasis in cervical cancer. Eur J Gynecol Oncol 2007, 18:33-38.
33. Schwarz J.K., Siegel B.A., Dehdashti F., Grigsby P.W. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007, 298:2289-2295.
34. Lai C.H., Huang K.G., See L.C., Yen T.C., Ma S.Y., Tsai C.S., et al. Restaging of recurrent cervical cancer with dual-phase positron emission tomography. Cancer 2004, 100:544-545.
35. Chang T.C., Law K.S., Hong J.H., Lai C.H., Yen T.C., Ng K.K., et al. Positron emission tomography for unexplained serum SCC-Ag elevation in cervical cancer patients-a phase II study. Cancer 2004, 101:164-171.
36. Lin C.T., Yen T.C., Chang T.C., Ng K.K., Tsai C.S., Ho K.C., et al. Role of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer 2006, 16:1994-2003.
37. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., Ihling C., Högerle S., Mix M., et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001, 218:776-782.
38. Goyal B.K., Singh H., Kapur K., Ihling C., Högerle S., Mix M., et al. Value of PET-CT in avoiding multimodality therapy in operable cervical cancer. Int J Gynecol Cancer 2010, 20:1041-1045.
39. Chou H.H., Chang H.P., Lai C.H., Ng K.K., Hsueh S., Wu T.I., et al. (18)F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma. Eur J Nucl Med Mol Imaging 2010, 37:728-735.
40. Chou H.H., Chang T.C., Yen T.C., Ng K.K., Ma S.Y., Hsueh S., et al. Low value of 2-fluoro-2-deoxy-d-glucose positron emission tomography in primary staging of early-stage cervical cancer prior to radical hysterectomy. J Clin Oncol 2006, 24:123-128.
41. Ryu S.Y., Kim M.H., Choi S.C., Choi C.W., Lee K.H. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003, 44:347-352.
42. Havrilesky L.J., Wong T.Z., Secord A.A., Berchuck A., Clarke-Pearson D.L., Jones E.L. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003, 90:186-190.
43. Schwarz J.K., Lin L.L., Siegel B.A., Miller T.R., Grigsby P.W. 18-f-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2009, 72:1502-1507.
44. Lai C.H., Yen T.C. When and how often should PET scans be performed in the management of cervical cancer?. Exp Rev Anticancer Ther 2010, 10:983-986.
45. Vargas H.A., Akin O., Zheng J., Moskowitz C., Soslow R., Abu-Rustum N., et al. The value of MR imaging when the site of uterine cancer origin is uncertain. Radiology 2011, 258:785-792.
46. Rockall A.G., Sohaib S.A., Harisinghani M.G., Babar S.A., Singh N., Jeyarajah A.R., et al. Diagnostic performance of nanoparticle-enhance magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005, 23:2813-2821.
47. Hori M., Kim T., Murakami T., Imaoka I., Onishi H., Nakamoto A., et al. Uterine cervical carcinoma: preoperative staging with 3.0-T MR imaging-comparison with 1.5-T MR imaging. Radiology 2009, 251:96-104.
48. Lin G., Ho K.C., Wang J.J., Ng K.K., Wai Y.Y., Chen Y.T., et al. Detection of lymph node metastasis in gynecologic cancer by diffusion-weighted magnetic resonance imaging at 3 Tesla. JMRI 2008, 28:128-135.
49. Levy A., Caramella C., Chargari C., Medjhoul A., Rey A., Zareski E., et al. Accuracy of diffusion-weighted echo-planar MR imaging and ADC mapping in the evaluation of residual cervical carcinoma after radiation therapy. Gynecol Oncol 2011, 123:110-115.
50. Ho K.C., Lin G., Wang J.J., Lai C.H., Chang C.J., Yen T.C. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med 2009, 36:200-208.
51. Small W., Vern T.Z., Rademake A., Nemcek A., Spies S., Schink J.C., et al. A prospective trial comparing lymphangiogram, cross-sectionalimaging, and positron emission tomography scan in the detection of lymph node metastasis in locally advanced cervical cancer. Am J Clin Oncol 2010, 33:89-93.
52. Chung H.H., Kang K.W., Cho J.Y., Kim J.W., Park N.H., Song Y.S., et al. Role of magnetic resonance imaging and positron emission tomography/computed tomography in preoperative lymph node detection of uterine cervical cancer. Am J Obstet Gynecol 2010, 203:156.e1-156.e5.
53. Menda Y., Boles Ponto L.L., Dornfeld K.J., Tewson T.J., Watkins G.L., Schultz M.K., et al. Kinetic analysis of 39-deoxy-39-18F-fluorothymidine (18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med 2009, 50:1028-1035.
54. Mankoff D.A. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res 2008, 10(1):S3.
55. Eckelman W.C., Reba R.C., Kelloff G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 2008, 13:748-759.
56. Massague J. TGFβ in cancer. Cell 2008, 134:215-230.
57. Ruggiero A., Holland J.P., Judolin T., Shenker L., Koulova A., Bander N.H., et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 2011, 52:1608-1615.
58. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med 2011, 52:1173-1180.
59. Kurhanewicz J., Vigneron D.B., Brindle K., Chekmenev E.Y., Comment A., Cunningham C.H., et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011, 13:81-97.
60. Salomon A., Goedicke A., Schweizer B., Aach T., Schulz V. Simultaneous reconstruction of activity and attenuation for PET/MR. IEEE Trans Med Imaging 2011, 30:804-813.
61. Li S.P., Taylor N.J., Makris A., Ah-See M.L., Beresford M.J., Stirling J.J., et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 2011, 257:643-652.
62. Kyriazi S., Collins D.J., Messiou C., Pennert K., Davidson R.L., Giles S.L., et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology 2011, 261:182-192.
63. Chen JH, Bahri S, Mehta RS, Kuzucan A, Yu HJ, Carpenter PM, et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging [published online ahead of pring August 30, 2011]. Radiology.
64. Yabroff K.R., Schrag D. Challenges and opportunities for use of cost-effectiveness analysis. J Natl Cancer Inst 2009, 101:1161-1163.
65. Uyl-de Groot C.A., Senft A., de Bree R., Leemans C.R., Hoekstra O.S. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med 2010, 51:176-182.
66. Cerci J.J., Trindade E., Pracchia L., Pitella F.A., Linardi C.C., Soares J., et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol 2010, 28:1415-1421.